SHTDF (Sinopharm Group Co) GF Score : 86/100 (As of Apr. 01, 2025)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co GF Score?

Sinopharm Group Co has the GF Score of 86, which implies that the company might have Good outperformance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 9/10
3. Growth Rank : 9/10
4. GF Value Rank : 9/10
5. Momentum Rank : 2/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Sinopharm Group Co might have Good outperformance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Sinopharm Group Co's GF Score

For the Medical Distribution subindustry, Sinopharm Group Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinopharm Group Co's GF Score Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's GF Score distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's GF Score falls into.

Save Embed

;

Save Embed

;

Sinopharm Group Co (OTCPK:SHTDF) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Sinopharm Group Co GF Score Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDF) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

SHTDY:USA 01099:Hong Kong X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Sinopharm Group Co Headlines

From GuruFocus

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon • 05-19-2016

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon • 10-18-2014

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan • 10-20-2014

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon • 05-19-2016

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 01-25-2021

Sinopharm Group Co Ltd's Dividend Analysis

By GuruFocus Research • 06-17-2024

Arnold Van Den Berg Buys Prem Watsa's Fairfax India, 3 Other Stocks in 3rd Quarter

By Holly LaFon Holly LaFon • 10-31-2017

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood • 07-30-2020